Relay Therapeutics Files 2024 10-K, Reports on Offerings

Ticker: RLAY · Form: 10-K · Filed: Feb 26, 2025 · CIK: 1812364

Relay Therapeutics, Inc. 10-K Filing Summary
FieldDetail
CompanyRelay Therapeutics, Inc. (RLAY)
Form Type10-K
Filed DateFeb 26, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, biotech, offering, collaboration

Related Tickers: RLAY

TL;DR

Relay Tx (RLAY) filed its 2024 10-K. Key events: Sept 2024 follow-on offering & Genentech deal.

AI Summary

Relay Therapeutics, Inc. filed its 2024 10-K on February 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, located at 399 Binney Street, Cambridge, MA, is involved in biological products. Key events mentioned include a follow-on offering in September 2024 and a Genentech agreement related to the transfer of active pharmaceutical ingredients.

Why It Matters

This filing provides investors with a comprehensive overview of Relay Therapeutics' financial health, strategic initiatives, and risks for the fiscal year 2024, impacting investment decisions.

Risk Assessment

Risk Level: medium — As a biotechnology company, Relay Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 2024 — Fiscal Year End (Reporting period for the 10-K)
  • 2025-02-26 — Filing Date (Date the 10-K was submitted to the SEC)

Key Players & Entities

  • Relay Therapeutics, Inc. (company) — Filer of the 10-K
  • 2024-12-31 (date) — Fiscal year end
  • 2025-02-26 (date) — Filing date
  • 399 Binney Street, Cambridge, MA (location) — Company business address
  • Genentech (company) — Party to an agreement
  • September 2024 (date) — Follow-on offering period

FAQ

What was the primary purpose of the Genentech agreement mentioned in the filing?

The filing mentions a Genentech agreement related to the 'TransferOfActivePharmaceuticalIngredientMember'.

When did Relay Therapeutics conduct a follow-on offering?

A follow-on offering is mentioned in the context of the period between September 1, 2024, and September 30, 2024.

What is Relay Therapeutics' Standard Industrial Classification code?

Relay Therapeutics' SIC code is 2836, categorized under Biological Products (No Diagnostic Substances).

Where is Relay Therapeutics headquartered?

Relay Therapeutics is headquartered at 399 Binney Street, 2nd Floor, Cambridge, MA 02139.

What is the SEC file number for this 10-K filing?

The SEC file number for this filing is 001-39385.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 26, 2025 regarding Relay Therapeutics, Inc. (RLAY).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.